AU2015270396B2 - Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism - Google Patents

Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism Download PDF

Info

Publication number
AU2015270396B2
AU2015270396B2 AU2015270396A AU2015270396A AU2015270396B2 AU 2015270396 B2 AU2015270396 B2 AU 2015270396B2 AU 2015270396 A AU2015270396 A AU 2015270396A AU 2015270396 A AU2015270396 A AU 2015270396A AU 2015270396 B2 AU2015270396 B2 AU 2015270396B2
Authority
AU
Australia
Prior art keywords
complement
protein
seq
amino acids
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015270396A
Other languages
English (en)
Other versions
AU2015270396A1 (en
Inventor
Wynne H Weston-Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of AU2015270396A1 publication Critical patent/AU2015270396A1/en
Application granted granted Critical
Publication of AU2015270396B2 publication Critical patent/AU2015270396B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2015270396A 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism Active AU2015270396B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
GB1410116.6 2014-06-06
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Publications (2)

Publication Number Publication Date
AU2015270396A1 AU2015270396A1 (en) 2016-12-15
AU2015270396B2 true AU2015270396B2 (en) 2020-07-16

Family

ID=51266841

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015270396A Active AU2015270396B2 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism

Country Status (16)

Country Link
US (3) US11052129B2 (enExample)
EP (1) EP3151851B1 (enExample)
JP (2) JP7045133B2 (enExample)
KR (1) KR102439717B1 (enExample)
CN (1) CN106659767B (enExample)
AU (1) AU2015270396B2 (enExample)
BR (1) BR112016028446A2 (enExample)
CA (1) CA2951175A1 (enExample)
DK (2) DK3151851T3 (enExample)
ES (2) ES2906630T3 (enExample)
GB (1) GB201410116D0 (enExample)
IL (1) IL249237B (enExample)
MX (1) MX382757B (enExample)
PL (2) PL3151851T3 (enExample)
RU (1) RU2700932C2 (enExample)
WO (1) WO2015185760A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2019521105A (ja) * 2016-06-07 2019-07-25 ノバルティス アーゲー 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体
SE540754C2 (en) * 2016-11-30 2018-10-30 Ikea Supply Ag Molding of fiber blanks into three-dimensional fiber block
ES2945433T3 (es) * 2017-04-21 2023-07-03 Volution Immuno Pharmaceuticals Sa Coversina para el tratamiento de enfermedades ampollares autoinmunes
JP7153669B2 (ja) * 2017-04-21 2022-10-14 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 瘢痕性眼炎症障害の治療のためのコバーシン
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
EP3849588A1 (en) * 2018-09-10 2021-07-21 Volution Immuno Pharmaceuticals SA Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014047500A1 (en) * 2012-09-21 2014-03-27 Alexion Pharmaceuticals, Inc. Screening assays for complement component c5 antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
DE602004020334D1 (de) 2003-06-02 2009-05-14 Varleigh Ltd Komplementinhibitoren aus zecken
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
WO2008029169A2 (en) 2006-09-08 2008-03-13 Varleigh Limited Method of treating respiratory disorders
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
NZ601018A (en) * 2010-01-08 2013-09-27 Varleigh Immuno Pharmaceuticals Ltd Ev576 for use in the treatment of viral infections of the respiratory tract
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
ES2945433T3 (es) 2017-04-21 2023-07-03 Volution Immuno Pharmaceuticals Sa Coversina para el tratamiento de enfermedades ampollares autoinmunes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014047500A1 (en) * 2012-09-21 2014-03-27 Alexion Pharmaceuticals, Inc. Screening assays for complement component c5 antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FREDSLUND, Folmer et al., Structure of and influence of a tick complement inhibitor on human complement component 5. NATURE IMMUNOLOGY, 2008, vol. 9, no. 7, pages 753-760 *
NISHIMURA, Jun-Ichi et al., Genetic Variants in C5 and Poor Response to Eculizumab. NEW ENGLAND JOURNAL OF MEDICINE, 13 February 2014, vol. 370, no. 7, pages 632-639 *
ROVERSI, Pietro et al., The Structure of OMCI, a Novel Lipocalin Inhibitor of the Complement System. JOURNAL OF MOLECULAR BIOLOGY, 2007, vol. 369, no. 3, pages 784-793 *

Also Published As

Publication number Publication date
JP6767396B2 (ja) 2020-10-14
KR102439717B1 (ko) 2022-09-02
WO2015185760A1 (en) 2015-12-10
IL249237B (en) 2020-09-30
NZ727053A (en) 2023-10-27
DK3151851T3 (da) 2022-02-28
US11052129B2 (en) 2021-07-06
PL3302519T3 (pl) 2022-04-25
DK3302519T3 (da) 2022-02-28
JP7045133B2 (ja) 2022-03-31
ES2906632T3 (es) 2022-04-19
RU2016151179A (ru) 2018-07-16
KR20170016893A (ko) 2017-02-14
CN106659767B (zh) 2022-08-30
MX382757B (es) 2025-03-13
GB201410116D0 (en) 2014-07-23
CN106659767A (zh) 2017-05-10
JP2017518316A (ja) 2017-07-06
US20180193417A1 (en) 2018-07-12
JP2018516944A (ja) 2018-06-28
US20210283221A1 (en) 2021-09-16
RU2016151179A3 (enExample) 2019-01-22
AU2015270396A1 (en) 2016-12-15
MX2016016139A (es) 2017-07-28
IL249237A0 (en) 2017-02-28
RU2700932C2 (ru) 2019-09-24
US20170196936A1 (en) 2017-07-13
PL3151851T3 (pl) 2022-04-04
CA2951175A1 (en) 2015-12-10
ES2906630T3 (es) 2022-04-19
EP3151851B1 (en) 2021-12-01
EP3151851A1 (en) 2017-04-12
BR112016028446A2 (pt) 2017-10-24

Similar Documents

Publication Publication Date Title
AU2015270396B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism
AU2007293239B2 (en) Method of treating peripheral nerve disorders
US20240009270A1 (en) Coversin for the treatment of autoimmune blistering diseases
JP5784078B2 (ja) 呼吸器疾患の治療方法
EP3302519B1 (en) Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
NZ727053B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism
KR20190126801A (ko) 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)